TLDR
- Both pharmaceutical companies received Outperform ratings from Wolfe Research with identical $300 price objectives
- Key experimental treatments litifilimab and felzartamab position Biogen for future growth in underserved markets
- Extended patent exclusivity for Rinvoq through 2037 eliminates significant revenue risk for AbbVie
- AbbVie’s second-quarter revenue hit $16.99 billion, representing a 10.2% annual increase and surpassing expectations
- Biogen delivered stronger-than-anticipated Q2 results with earnings per share of $3.60 against consensus of $2.94
On Thursday, Wolfe Research elevated its stance on both Biogen and AbbVie, assigning Outperform ratings to each pharmaceutical company alongside $300 price objectives. The analyst firm pointed to robust development pipelines, compelling market valuations, and anticipated clinical trial results as primary justifications.
Pipeline Assets Position Biogen for Growth Trajectory
Biogen shares have been trading below broader market multiples, a valuation gap that Wolfe Research believes fails to account for the company’s developmental portfolio. The firm elevated its stance from Peer Perform while establishing a $300 price objective.
Wolfe’s investment thesis centers on two experimental therapies. Litifilimab has the potential to become the inaugural biologic treatment authorized for cutaneous lupus erythematosus. Meanwhile, felzartamab could tackle antibody-mediated rejection in a commercial opportunity that analysts suggest Wall Street has underestimated.
The company’s acquisition of Apellis Pharmaceuticals bolsters its immediate revenue prospects through two marketed products, Empaveli and Syfovre.
Recent quarterly performance exceeded Wall Street projections. The company delivered earnings per share of $3.60 compared to analyst consensus of $2.94, while revenue reached $2.74 billion, marking a 3.4% year-over-year increase. Management has established fiscal 2026 earnings guidance in the $12.00 to $13.00 per share range.
Institutional investors hold 87.93% of Biogen’s outstanding shares. During the second quarter, Handelsbanken Fonder expanded its position by 12.7%, accumulating 93,236 shares valued at approximately $20.14 million.
Analyst consensus points to a Moderate Buy recommendation, with the average price target sitting at $224.61. Trading commenced Thursday at $208.87, approaching the 52-week peak of $219.72.
Extended Patent Timeline and Revenue Momentum Support AbbVie Thesis
Wolfe Research similarly upgraded AbbVie from Peer Perform to Outperform. The firm argued that AbbVie’s 2027 earnings multiple of 14.6 times appears undervalued for an organization projected to generate high-single-digit revenue expansion throughout the decade.
Intellectual property protection represents a critical upgrade factor. Generic competition for Rinvoq has been delayed until 2037, while AbbVie actively defends Skyrizi’s patent exclusivity. This timeline suggests the company may avoid significant patent expiration challenges during the current decade.
Second-quarter financial results showed revenue of $16.99 billion, climbing 10.2% year-over-year and exceeding analyst consensus of $16.80 billion. Earnings per share reached $3.65, slightly above the $3.61 projection.
Skyrizi and Rinvoq continue driving top-line performance. Additionally, Canada’s Drug Agency issued a positive reimbursement recommendation for Ubrelvy in acute migraine management, creating another revenue opportunity.
Shareholders approved the company’s acquisition of Apogee Therapeutics, though the transaction introduces approximately $8 billion in additional debt, which some analysts identify as a potential execution challenge.
AbbVie maintains a consensus Moderate Buy rating with an average analyst price target of $274.33. Shares opened Thursday’s session at $249.12.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
